Zai Lab Limited (ZLAB)
| Market Cap | 2.88B -21.9% |
| Revenue (ttm) | 449.61M +5.1% |
| Net Income | -188.21M |
| EPS | -1.70 |
| Shares Out | 112.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,151,368 |
| Open | 25.43 |
| Previous Close | 26.01 |
| Day's Range | 25.25 - 25.96 |
| 52-Week Range | 15.96 - 35.45 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 32.39 (+26.33%) |
| Earnings Date | Aug 6, 2026 |
About ZLAB
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price target is $32.39, which is an increase of 26.33% from the latest price.
News
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Pha...
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript
Zoci advances toward global registrational trials as net product revenue rises 11%.
Zai Lab Q2 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a glob...
Zai Lab price target raised to $45 from $44 at Citi
Citi raised the firm’s price target on Zai Lab (ZLAB) to $45 from $44 and keeps a Buy rating on the shares. The Q2 report shows Zai is transitioning from…
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street e...
Zai Lab Earnings Call Transcript: Q2 2026
Net product revenue rose 11% sequentially to $105.8 million, with commercial profitability maintained and a strong cash position of $717.5 million. Pipeline progress includes three registrational oncology programs by year-end and first U.S. regulatory submission expected next year.
Zai Lab Earnings release: Q2 2026
Zai Lab released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zai Lab Quarterly report: Q2 2026
Zai Lab has published its Q2 2026 quarterly earnings report on August 6, 2026.
Zai Lab Slides: Q2 2026
Zai Lab has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Is Zai Lab Ltd (ZLAB) Positioned for Growth After Q2 Earnings Report? GF Score: 68/100, Revenue ...
Is Zai Lab Ltd (ZLAB) Positioned for Growth After Q2 Earnings Report? GF Score: 68/100, Revenue Beats Estimates
Zai Lab reports Q2 EPS (46c), consensus (68c)
Reports Q2 revenue $106.3M, consensus $103.8M. “Zai Lab (ZLAB) is entering an exciting new chapter in our evolution,” said CEO Samantha Du. “Today, our innovation pipeline is rapidly maturing. We…
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2026, along with recent product highlights and corp...
Zai Lab says FDA grants Orphan Drug Designation for zocilurtatug pelitecan
Zai Lab (ZLAB) announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3 antibody-drug c...
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilu...
Zai Lab treatment of neuroendocrine carcinoma granted FDA orphan designation
Zai Lab’s (ZLAB) zocilurtatug pelitecan was granted FDA orphan designation as a treatment of neuroendocrine carcinoma, according to a post to the agency’s website.
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2026 financial results and provide recent corporate upda...
Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB)
Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB)
Zai Lab Transcript: AGM 2026
The meeting confirmed a quorum and approved all fourteen proposals, including director reelections, auditor appointments, executive compensation, and mandates for share issuance and repurchase. No shareholder questions were raised, and all resolutions passed as ordinary resolutions.
Zai Lab announces EMA granted ODD to zocilurtatug pelitecan
Zai Lab (ZLAB) announced the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3-targeting a...
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug p...
Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment
Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License...
Zai Lab (ZLAB) Q1 2026 Earnings Transcript
Zai Lab (ZLAB) Q1 2026 Earnings Transcript